Compounds > sinularin
Page last updated: 2024-12-11

sinularin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sinularin: has antineoplastic activity; isolated from the soft coral Sinularia flexibilis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5477029
MeSH IDM0576346

Synonyms (4)

Synonym
sinularin
nsc-285706
5,6]octadec-9-en-16-one, 13-hydroxy-4,9,13-trimethyl-17-methylene-, [1r-(1r*,4s*,6s*,9e,13s*,14r*)]-
(9e)-13-hydroxy-4,9,13-trimethyl-17-methylidene-5,15-dioxatricyclo[12.3.1.04,6]octadec-9-en-16-one

Research Excerpts

Overview

Sinularin is an active compound isolated from the cultured soft coral Sinularia flexibilis. It has anticancer activity in many cancer cells.

ExcerptReferenceRelevance
"Sinularin is a soft coralsderived natural compound that has anticancer activity in many cancer cells."( Sinularin Exerts Anti-cancer Effects by Inducing Oxidative Stress-mediated Ferroptosis, Apoptosis, and Autophagy in Prostate Cancer Cells.
An, L; Chen, CY; Chen, H; Chen, X; Lin, Y; Liu, CM; Liu, X; OuYang, AJ; Shao, Z; Su, M; Wu, Z, 2023)		3.07
"Sinularin is an active compound isolated from the cultured soft coral Sinularia flexibilis. "( Sinularin Induces Apoptosis through Mitochondria Dysfunction and Inactivation of the pI3K/Akt/mTOR Pathway in Gastric Carcinoma Cells.
Lu, CI; Weng, SH; Wong, BS; Wu, YJ; Yea, SH, 2016)		3.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (70.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.53 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hexamethonium
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.		2.110quaternary ammonium salt
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.1510acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.610
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.610
Benign Neoplasms
[description not available]		02.3110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.3110
Cancer of Mouth
[description not available]		02.1510
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.1510
Breast Cancer
[description not available]		07.1710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1710
Cancer of Stomach
[description not available]		02.1310
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.1310
Hepatocellular Carcinoma
[description not available]		07.1510
Cancer of Liver
[description not available]		02.1510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1510
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1510
Malignant Melanoma
[description not available]		02.0710
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.0710
Nociceptive Pain
Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.		02.0710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0710
Anasarca
[description not available]		02.0710
Allodynia
[description not available]		02.0710
Innate Inflammatory Response
[description not available]		02.0710
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.0710